Guangzhou Baiyunshan Pharmaceutical Holdings Valuation
Is 874 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 874 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 874 (HK$18.1) is trading above our estimate of fair value (HK$9.71)
Significantly Below Fair Value: 874 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 874?
Key metric: As 874 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 874's PE Ratio? | |
|---|---|
| PE Ratio | 8x |
| Earnings | CN¥3.42b |
| Market Cap | CN¥44.12b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.6x |
| Enterprise Value/EBITDA | 9.2x |
| PEG Ratio | 0.7x |
Price to Earnings Ratio vs Peers
How does 874's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 10.9x | ||
1099 Sinopharm Group | 7.1x | 4.5% | HK$64.6b |
1931 IVD Medical Holding | 10.3x | n/a | HK$2.7b |
3390 Tycoon Group Holdings | 12.4x | n/a | HK$2.9b |
1345 Shanghai Pioneer Holding | 13.6x | n/a | HK$2.4b |
874 Guangzhou Baiyunshan Pharmaceutical Holdings | 8x | 11.3% | HK$47.9b |
Price-To-Earnings vs Peers: 874 is good value based on its Price-To-Earnings Ratio (8x) compared to the peer average (10.9x).
Price to Earnings Ratio vs Industry
How does 874's PE Ratio compare vs other companies in the HK Healthcare Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
574 Pa Shun International Holdings | 2x | n/a | US$7.96m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 874 is good value based on its Price-To-Earnings Ratio (8x) compared to the Hong Kong Healthcare industry average (13.1x).
Price to Earnings Ratio vs Fair Ratio
What is 874's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 8x |
| Fair PE Ratio | 14.6x |
Price-To-Earnings vs Fair Ratio: 874 is good value based on its Price-To-Earnings Ratio (8x) compared to the estimated Fair Price-To-Earnings Ratio (14.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | HK$18.10 | HK$21.44 +18.5% | 15.0% | HK$25.98 | HK$16.90 | n/a | 4 |
| Nov ’25 | HK$18.34 | HK$21.44 +16.9% | 15.0% | HK$25.98 | HK$16.90 | n/a | 4 |
| Oct ’25 | HK$20.60 | HK$23.59 +14.5% | 21.0% | HK$31.66 | HK$17.04 | n/a | 5 |
| Sep ’25 | HK$19.44 | HK$25.63 +31.9% | 13.6% | HK$30.95 | HK$20.00 | n/a | 5 |
| Aug ’25 | HK$19.76 | HK$25.63 +29.7% | 13.6% | HK$30.95 | HK$20.00 | n/a | 5 |
| Jul ’25 | HK$20.65 | HK$25.85 +25.2% | 1.2% | HK$26.16 | HK$25.42 | n/a | 3 |
| Jun ’25 | HK$22.25 | HK$23.91 +7.5% | 10.4% | HK$26.20 | HK$20.08 | n/a | 4 |
| May ’25 | HK$20.90 | HK$23.87 +14.2% | 10.2% | HK$26.05 | HK$20.09 | n/a | 4 |
| Apr ’25 | HK$19.24 | HK$23.97 +24.6% | 10.1% | HK$26.20 | HK$20.20 | n/a | 4 |
| Mar ’25 | HK$21.20 | HK$25.33 +19.5% | 12.2% | HK$28.26 | HK$20.51 | n/a | 4 |
| Feb ’25 | HK$19.32 | HK$25.33 +31.1% | 12.2% | HK$28.26 | HK$20.51 | n/a | 4 |
| Jan ’25 | HK$21.75 | HK$25.33 +16.5% | 12.2% | HK$28.26 | HK$20.51 | n/a | 4 |
| Dec ’24 | HK$21.65 | HK$26.19 +21.0% | 12.8% | HK$30.08 | HK$20.00 | n/a | 5 |
| Nov ’24 | HK$21.05 | HK$25.96 +23.3% | 13.0% | HK$29.91 | HK$19.71 | HK$18.34 | 5 |
| Oct ’24 | HK$22.55 | HK$26.05 +15.5% | 13.1% | HK$29.93 | HK$19.72 | HK$20.60 | 5 |
| Sep ’24 | HK$22.05 | HK$26.36 +19.5% | 13.1% | HK$30.18 | HK$19.89 | HK$19.44 | 5 |
| Aug ’24 | HK$23.10 | HK$26.94 +16.6% | 13.5% | HK$30.52 | HK$20.07 | HK$19.76 | 5 |
| Jul ’24 | HK$23.65 | HK$26.16 +10.6% | 17.0% | HK$30.22 | HK$18.78 | HK$20.65 | 4 |
| Jun ’24 | HK$25.15 | HK$25.66 +2.0% | 19.0% | HK$31.01 | HK$19.27 | HK$22.25 | 4 |
| May ’24 | HK$25.75 | HK$24.44 -5.1% | 18.2% | HK$30.40 | HK$19.73 | HK$20.90 | 3 |
| Apr ’24 | HK$24.20 | HK$24.74 +2.2% | 18.0% | HK$30.69 | HK$20.00 | HK$19.24 | 3 |
| Mar ’24 | HK$23.85 | HK$23.00 -3.6% | 10.4% | HK$26.34 | HK$20.98 | HK$21.20 | 3 |
| Feb ’24 | HK$23.25 | HK$23.00 -1.1% | 10.4% | HK$26.34 | HK$20.98 | HK$19.32 | 3 |
| Jan ’24 | HK$23.00 | HK$23.00 -0.004% | 10.4% | HK$26.34 | HK$20.98 | HK$21.75 | 3 |
| Dec ’23 | HK$22.80 | HK$22.49 -1.3% | 10.7% | HK$25.75 | HK$20.03 | HK$21.65 | 3 |
| Nov ’23 | HK$18.08 | HK$22.08 +22.1% | 11.3% | HK$25.57 | HK$19.88 | HK$21.05 | 3 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Sinopharm Group
HK$64.6b
Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.
1099
HK$21.30
7D
2.4%
1Y
7.8%
OrbusNeich Medical Group Holdings
HK$3.6b
An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.
6929
HK$4.12
7D
0%
1Y
-47.8%
MicroPort Scientific
HK$11.2b
An investment holding company, engages in the manufacture, marketing, and sale of medical devices in the People’s Republic of China, North America, Europe, rest of Asia, South America, and internationally.
853
HK$6.26
7D
-3.4%
1Y
-51.8%